Our Blog Archives - Clinion

4 Benefits of Using ePRO During the COVID-19 Pandemic

There are many benefits by using Clinion ePRO During the COVID-19 Pandemic During the ongoing COVID-19 crisis, CROs and Pharmaceutical companies are facing myriad of challenges. Many clinical trial studies have either slowed down or completely stopped due to the...
Read more

Clinion is supporting researchers in their fight against the Covid-19 pandemic.

The Clinion EDC platform is being offered to researchers at a discounted price in their fight against the Covid-19 virus. As of May 15, Clinion is already supporting multiple Covid-19 studies. We have developed a mobile Patient Reported Outcomes (ePRO)...
Read more

Why Implement an FDA 21 CFR Part 11 Software System

To be compliant with US FDA 21 CFR Part 11 regulations, CFR Part 11 validation of electronic data management systems is mandatory. In simple terms, any computerized system involved in the clinical research process must comply with FDA 21 CFR...
Read more

Benefits of a Clinical Trial Management System

Clinion CTMS – Discover, Transform and Enhance your Clinical Trials Clinical Trials are a humongous undertaking. They involve massive amounts of data, hundreds of people and many sites for investigation. Managing these trials in the highly regulated clinical research field...
Read more

Implementing a Clinical Data Management System (CDMS)

Clinion CDMS – Solutions to deliver high quality, quick and productive clinical studiesWe at Clinion understand how clinical data can completely impact the cost, effectiveness and turnaround time of any clinical study. Clinion’s Clinical Data Management System (CDMS) works towards...
Read more

Benefits of Electronic Data Capture

Electronic Data Capture(EDC) is used to help medical device and pharmaceutical organizations accomplish the greatest effectiveness with regards to entering data, structuring a database and conducting analysis for clinical trials. EDC technology has developed as past worries about data integrity...
Read more